Markers of tyrosine kinase activity in eosinophilic esophagitis: A pilot study of the FIP1L1-PDGFRα fusion gene, pERK 1/2, and pSTAT5

Diseases of the Esophagus

Volumn 25, Issue 2, 2012, Pages 166-174

  Dellon, E S ^a   Bower, J J ^a   Keku, T O ^a   Chen, X ^a,b   Miller, C R ^a   Woosley, J T ^a   Orlando, R C ^a   Shaheen, N J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

Eosinophilic esophagitis; ERK 1 2; Gastresophageal reflux disease; STAT5; Tyrosine kinase

Indexed keywords

FIP1 LIKE 1 PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA FUSION PROTEIN; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; EOSINOPHILIC ESOPHAGITIS; ESOPHAGUS BIOPSY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; EOSINOPHILIC ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; PILOT PROJECTS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RETROSPECTIVE STUDIES; STAT5 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84857117878     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2011.01230.x     Document Type: Article

References (43)

1. Furuta G T, Liacouras C A, Collins M H etal. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007; 133: 1342-63.
2. Liacouras C A, Furuta G T, Hirano I etal. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128: 3-20.e6.
3. Straumann A, Bauer M, Fischer B, Blaser K, Simon H U. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol 2001; 108: 954-61.
4. Mishra A, Hogan S P, Brandt E B, Rothenberg M E. An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest 2001; 107: 83-90.
5. Straumann A, Kristl J, Conus S etal. Cytokine expression in healthy and inflamed mucosa: probing the role of eosinophils in the digestive tract. Inflamm Bowel Dis 2005; 11: 720-6.
6. Gupta S K, Fitzgerald J F, Kondratyuk T, HogenEsch H. Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2006; 42: 22-6.
7. Blanchard C, Wang N, Stringer K F etal. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006; 116: 536-47.
8. Rothenberg M E. Biology and treatment of eosinophilic esophagitis. Gastroenterology 2009; 137: 1238-49.
9. Markowitz J E, Spergel J M, Ruchelli E, Liacouras C A. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol 2003; 98: 777-82.
10. Liacouras C A, Spergel J M, Ruchelli E etal. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005; 3: 1198-206.
11. Kagalwalla A F, Sentongo T A, Ritz S etal. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006; 4: 1097-102.
12. Gonsalves N, Yang G-Y, Doerfler B, Ritz S, Ditto A M, Hirano I. A prospective clinical trial of six food elimination diet and reintroduction of causative agents in adults with eosinophilic esophagitis. Gastroenterology 2008; 134 (Suppl 1): S104-5 (A727).
13. Penfield J D, Lang D M, Goldblum J R, Lopez R, Falk G W. The role of allergy evaluation in adults with eosinophilic esophagitis. J Clin Gastroenterol 2010; 44: 22-7.
14. Roy-Ghanta S, Larosa D F, Katzka D A. Atopic characteristics of adult patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2008; 6: 531-5.
15. Assa'ad A H, Putnam P E, Collins M H etal. Pediatric patients with eosinophilic esophagitis: an 8-year follow-up. J Allergy Clin Immunol 2007; 119: 731-8.
16. Spergel J M, Brown-Whitehorn T F, Beausoleil J L etal. 14 years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr 2009; 48: 30-6.
17. Dellon E S, Gibbs W B, Fritchie K J etal. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2009; 104: 2695-703.
18. Konikoff M R, Noel R J, Blanchard C etal. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006; 131: 1381-91.
19. Straumann A, Conus S, Degen L etal. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010; 139: 1526-37, 37 e1.
20. Cools J, DeAngelo D J, Gotlib J etal. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-14.
21. Gotlib J, Cools J, Malone J M, 3rd, Schrier S L, Gilliland D G, Coutre S E. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879-91.
22. Buitenhuis M, Verhagen L P, Cools J, Coffer P J. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 2007; 67: 3759-66.
23. Robyn J, Lemery S, McCoy J P etal. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol 2006; 132: 286-92.
24. Kirsch R, Bokhary R, Marcon M A, Cutz E. Activated mucosal mast cells differentiate eosinophilic (allergic) esophagitis from gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007; 44: 20-6.
25. Lucendo A J, Navarro M, Comas C etal. Immunophenotypic characterization and quantification of the epithelial inflammatory infiltrate in eosinophilic esophagitis through stereology: an analysis of the cellular mechanisms of the disease and the immunologic capacity of the esophagus. Am J Surg Pathol 2007; 31: 598-606.
26. Abonia J P, Blanchard C, Butz B B etal. Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol 2010; 126: 140-9.
27. Dellon E S, Chen X, Miller C R etal. Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease. Am J Gastroenterol 2011; 106: 264-71.
28. Dellon E S, Fritchie K J, Rubinas T C, Woosley J T, Shaheen N J. Inter- and intraobserver reliability and validation of a new method for determination of eosinophil counts in patients with esophageal eosinophilia. Dig Dis Sci 2010; 55: 1940-9.
29. Dellon E S, Aderoju A, Woosley J T, Sandler R S, Shaheen N J. Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. Am J Gastroenterol 2007; 102: 2300-13.
30. Kim E K, Choi E J. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405.
31. Geest C R, Coffer P J. MAPK signaling pathways in the regulation of hematopoiesis. J Leukoc Biol 2009; 86: 237-50.
32. Coskun M, Olsen J, Seidelin J B, Nielsen O H. MAP kinases in inflammatory bowel disease. Clin Chim Acta 2011; 412: 513-20.
33. Bates M E, Green V L, Bertics P J. ERK1 and ERK2 activation by chemotactic factors in human eosinophils is interleukin 5-dependent and contributes to leukotriene C(4) biosynthesis. J Biol Chem 2000; 275: 10968-75.
34. Cui C H, Adachi T, Oyamada H etal. The role of mitogen-activated protein kinases in eotaxin-induced cytokine production from bronchial epithelial cells. Am J Respir Cell Mol Biol 2002; 27: 329-35.
35. Langlois A, Chouinard F, Flamand N, Ferland C, Rola-Pleszczynski M, Laviolette M. Crucial implication of protein kinase C (PKC)-delta, PKC-zeta, ERK-1/2, and p38 MAPK in migration of human asthmatic eosinophils. J Leukoc Biol 2009; 85: 656-63.
36. Ohnishi H, Takeda K, Domenico J etal. Mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2-dependent pathways are essential for CD8+ T cell-mediated airway hyperresponsiveness and inflammation. J Allergy Clin Immunol 2009; 123: 249-57.
37. Adachi T, Choudhury B K, Stafford S, Sur S, Alam R. The differential role of extracellular signal-regulated kinases and p38 mitogen-activated protein kinase in eosinophil functions. J Immunol 2000; 165: 2198-204.
38. Moore P E, Church T L, Chism D D, Panettieri R A, Jr, Shore S A. IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK. Am J Physiol Lung Cell Mol Physiol 2002; 282: L847-53.
39. Zhu X, Jacobs B, Boetticher E etal. IL-5-induced integrin adhesion of human eosinophils caused by ERK1/2-mediated activation of cPLA2. J Leukoc Biol 2002; 72: 1046-53.
40. Kampen G T, Stafford S, Adachi T etal. Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood 2000; 95: 1911-7.
41. Mulder D J, Pacheco I, Hurlbut D J etal. FGF9-induced proliferative response to eosinophilic inflammation in oesophagitis. Gut 2009; 58: 166-73.
42. Huang J J, Joh J W, Fuentebella J etal. Eotaxin and FGF enhance signaling through an extracellular signal-related kinase (ERK)-dependent pathway in the pathogenesis of eosinophilic esophagitis. Allergy Asthma Clin Immunol 2010; 6: 25-33.
43. Cheung P F, Wong C K, Ip W K, Lam C W. FAK-mediated activation of ERK for eosinophil migration: a novel mechanism for infection-induced allergic inflammation. Int Immunol 2008; 20: 353-63.